Xanthohumol Prevents Atherosclerosis by Reducing Arterial Cholesterol Content via CETP and Apolipoprotein E in CETP-Transgenic Mice

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Hirata, Hiroshi ^a   Yimin, ^b   Segawa, Shuichi ^a   Ozaki, Moeko ^a   Kobayashi, Naoyuki ^a   Shigyo, Tatsuro ^a   Chiba, Hitoshi ^c  

^a SAPPORO BREWERIES LTD   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL; XANTHOHUMOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; BIOACCUMULATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; TREATMENT OUTCOME;

ANIMALS; AORTA, THORACIC; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOTTING, WESTERN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; DIET, ATHEROGENIC; ELECTROPHORESIS; FLAVONOIDS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROPIOPHENONES; REAL-TIME POLYMERASE CHAIN REACTION; TRANSITION TEMPERATURE;

MUS; MUS MUSCULUS;

EID: 84869232518     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049415     Document Type: Article

References (29)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR, (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 62: 707-714.
2. Libby P, Aikawa M, (2002) Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 8: 1257-62.
3. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, et al. (2007) Treating to New Targets Investigators. HDL-C, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 357: 1301-10.
4. Spieker LE, Ruschitzka F, Lüscher TF, Noll G, (2004) HDL and inflammation in atherosclerosis. Curr Drug Targets Immune Endocr Metabol Disord. 4: 51-7.
5. Lewis GF, Rader DJ, (2005) New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 96: 1221-32.
6. Tall AR, (1993) Plasma cholesteryl ester transfer protein. J Lipid Res. 34: 1255-74.
7. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, et al. (1989) Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 342: 448-451.
8. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, et al. (1990) Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 323: 1234-8.
9. Chiba H, Akita H, Tsuchihashi K, Hui SP, Takahashi Y, et al. (1997) Quantitative and compositional changes in high density lipoprotein subclasses in patients with various genotypes of cholesteryl ester transfer protein deficiency. J Lipid Res. 38: 1204-16.
10. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR, (2006) HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest. 116: 1435-42.
11. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, et al. (2000) A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406: 203-207.
12. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, et al. (2004) Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 24: 490-7.
13. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, et al. (1989) Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 342: 448-451.
14. Quinet E, Tall A, Ramakrishnan R, Rudel L, (1991) Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins. J Clin Invest. 87: 1559-66.
15. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, et al. (1993) Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 364: 73-5.
16. Brown MS, Goldstein JL, (1976) Receptor-mediated control of cholesterol metabolism. Science 191: 150-4.
17. Nicholls SJ, (2011) Apo A-I Modulating Therapies. Curr Cardiol Rep. 13: 537-43.
18. Dorn C, Kraus B, Motyl M, Weiss TS, Gehrig M, et al. (2010) Schölmerich J, Heilmann J, Hellerbrand C. Xanthohumol, a chalcon derived from hops, inhibits hepatic inflammation and fibrosis. Mol Nutr Food Res. 54: S205-13.
19. Tabata N, Ito M, Tomoda H, Omura S, (1997) Xanthohumols, diacylglycerol acyltransferase inhibitors, from Humulus lupulus. Phytochemistry. 46: 683-7.
20. Strathmann J, Klimo K, Sauer SW, Okun JG, Prehn JH, et al. (2010) Gerhäuser C. Xanthohumol-induced transient superoxide anion radical formation triggers cancer cells into apoptosis via a mitochondria-mediated mechanism. FASEB J. 24: 2938-50.
21. Hirata H, Takazumi K, Segawa S, Okada Y, Kobayashi N, et al (2012) Xanthohumol, a prenylated chalcone from Humulus lupulus L., inhibits cholesteryl ester transfer protein. Food Chem. 134: 1432-37.
22. Folch J, Lees M, Sloane Stanley GH, (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 226: 497-509.
23. Zhang B, Fan P, Shimoji E, Xu H, Takeuchi K, et al. (2004) Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler Thromb Vasc Biol. 24: 1910-5.
24. Hajime N, (2005) Xanthohumol, the chalcone from beer hops (Humulus lupulus L.), is the ligand for farnesoid × receptor and ameliorates lipid and glucose metabolism in KK-A(y) mice. Biochem Biophys Res Commun. 336: 754-61.
25. Hambruch E, Miyazaki-Anzai S, Hahn U, Matysik S, Boettcher A, et al. (2012) Synthetic FXR Agonists Induce HDL-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in CETP Transgenic LDLR-/- Mice. J Pharmacol Exp Ther. [Epub ahead of print].
26. Schwartz GG, (2012) New Horizons for Cholesterol Ester Transfer Protein Inhibitors. Curr Atheroscler Rep. 14: 41-8.
27. Mahley RW, Huang Y, Weisgraber KH, (2006) Putting cholesterol in its place: apoE and reverse cholesterol transport. J Clin Invest. 116: 1226-9.
28. Zhang Y, Yin L, Anderson J, Ma H, Gonzalez FJ, et al. (2010) Identification of Novel Pathways That Control Farnesoid × Receptor-mediated Hypocholesterolemia. J Biol Chem. 285: 3035-43.
29. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, et al. (2010) Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol. 30: 1430-8.